Gapping up
In reaction to strong earnings/guidance: DQ +10.8%, VRML +10.7%, RIOM +9.5%, CEP +7.9%, LIME +7.6%, YOD +7.5%, SKBI +5.6%, WYY +5.4%, SINA +5.2%, ADSK +4.4%, HTM +4.3%, AMAT +3.8%, XON +3.6%, AGRX +2.7%, ROX +2.7%, CHL +2.7%, UPIP +2.5%, LEI +2%, JCP +2%, KITE +1.7%, MNDL +1.4%, AEG +1.2%, SAND +1%, EL +0.8%, A +0.7%.
M&A news: MNST +20.3% (Monster Beverage and Coca-Cola enter into long-term strategic partnership), KO +1.8% (Monster Beverage and Coca-Cola enter into long-term strategic partnership).
Other news: ACHN +17.5% (achieves 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV), CRMD +8.2% (FDA accepted co's pivotal Phase 3 study protocol), FRO +4.3% (cont strength), SODA +3.7% (following MNST / KO ), GCI +2.3% (Icahn disclosed 6.63% active stake in 13D filing; supports split of the company), BHP +2.2% (announced update on portfolio; demerger of a selection of assets is co's preferred option), GLF +2% (to replace QCOR in the S&P SmallCap 600), DNOW +1.9% (new Berkshire Hathaway stake), PARR +1.9% (announced successful completion of common stock rights offering and award of $164 mln contract with Defense Logistics Agency Energy),MNK +1.9% (completes acquisition of Questcor (QCOR)), GILD +1.5% (disclosed favorable ruling in Roche (RHHBY) / Pharmasset case), CHTR +1% (new Berkshire Hathaway stake), EBAY +0.5% (may soon accept bitcoins at its payment unit, according to reports).
Analyst comments: CHL +2.7% (upgraded to Neutral from Underperform at Mizuho), UPL +1.8% (upgraded to Buy from Neutral at UBS ), GSJK +1.5% (upgraded to Overweight from Neutral at JP Morgan), MBI +1.2% (upgraded to Buy from Neutral at BTIG Research ), NXPI +0.8% (initiated with a Buy at Stifel)
In reaction to strong earnings/guidance: DQ +10.8%, VRML +10.7%, RIOM +9.5%, CEP +7.9%, LIME +7.6%, YOD +7.5%, SKBI +5.6%, WYY +5.4%, SINA +5.2%, ADSK +4.4%, HTM +4.3%, AMAT +3.8%, XON +3.6%, AGRX +2.7%, ROX +2.7%, CHL +2.7%, UPIP +2.5%, LEI +2%, JCP +2%, KITE +1.7%, MNDL +1.4%, AEG +1.2%, SAND +1%, EL +0.8%, A +0.7%.
M&A news: MNST +20.3% (Monster Beverage and Coca-Cola enter into long-term strategic partnership), KO +1.8% (Monster Beverage and Coca-Cola enter into long-term strategic partnership).
Other news: ACHN +17.5% (achieves 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV), CRMD +8.2% (FDA accepted co's pivotal Phase 3 study protocol), FRO +4.3% (cont strength), SODA +3.7% (following MNST / KO ), GCI +2.3% (Icahn disclosed 6.63% active stake in 13D filing; supports split of the company), BHP +2.2% (announced update on portfolio; demerger of a selection of assets is co's preferred option), GLF +2% (to replace QCOR in the S&P SmallCap 600), DNOW +1.9% (new Berkshire Hathaway stake), PARR +1.9% (announced successful completion of common stock rights offering and award of $164 mln contract with Defense Logistics Agency Energy),MNK +1.9% (completes acquisition of Questcor (QCOR)), GILD +1.5% (disclosed favorable ruling in Roche (RHHBY) / Pharmasset case), CHTR +1% (new Berkshire Hathaway stake), EBAY +0.5% (may soon accept bitcoins at its payment unit, according to reports).
Analyst comments: CHL +2.7% (upgraded to Neutral from Underperform at Mizuho), UPL +1.8% (upgraded to Buy from Neutral at UBS ), GSJK +1.5% (upgraded to Overweight from Neutral at JP Morgan), MBI +1.2% (upgraded to Buy from Neutral at BTIG Research ), NXPI +0.8% (initiated with a Buy at Stifel)